메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
대한안과학회 Korean Journal of Ophthalmology Korean Journal of Ophthalmology 제30권 제4호
발행연도
2016.1
수록면
265 - 271 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) is the first choice of treatment forage-related macular degeneration. However, quite a few eyes treated using conventional dose anti-VEGF(CDAV) have persistent pigment epithelial detachment (PED) on optical coherence tomography. This studyinvestigated the efficacy and safety of high dose anti-VEGF (HDAV) for refractory PED. Methods: In this retrospective study, 31 eyes of neovascular age-related macular degeneration patients withpersistent PED findings despite six or more intravitreal injections of CDAV (bevacizumab 1.25 mg or ranibizumab2.5 mg) were analyzed. Changes in visual outcome, central foveal thickness, and PED height werecompared before and after HDAV (bevacizumab 5.0 mg) for these refractory PED cases. Results: The mean age of patients was 67.7 years. The number of CDAV injections was 12.1. The number ofHDAV injections was 3.39. Best-corrected visual acuity in logarithm of the minimum angle of resolution beforeand after HDAV was 0.49 and 0.41 (p < 0.001), respectively. Central foveal thickness before and afterHDAV was 330.06 and 311.10 μm (p = 0.125), respectively. PED height before and after HDAV was 230.28 and204.07 μm (p = 0.014), respectively. There were no serious adverse reactions in all the eyes. Conclusions: Increasing the dose of bevacizumab in refractory PED may be a possible treatment option.

목차

등록된 정보가 없습니다.

참고문헌 (32)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0